Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
Juliette Lambert(Centre Hospitalier de Versailles), Sylvie Castaigné(Université Claude Bernard Lyon 1), Claude Preudhomme(Centre National de la Recherche Scientifique), Pascal Turlure(Centre Hospitalier Universitaire de Limoges), Ollivier Legrand(Sorbonne Université), Rebecca Benner(Pfizer (United States)), Cécile Pautas(Université Claude Bernard Lyon 1), Sylvie Chevret(Université Paris Cité), Claude Gardin(Université Sorbonne Paris Nord), Pierre Bousset(Pfizer (France)), Emmanuel Raffoux(Université Paris Cité), Xavier Thomas(Hôpital Lyon Sud), Karïn Gogat-Marchant(Pfizer (France)), Denis Caillot, Hervé Dombret(University of London Institute in Paris), Stephen D. Rubin(Pfizer (United States)), Christine Terré(Hôpital André Mignot)
Cited by 349
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k